Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Citi said Hikma Pharmaceuticals and Fresenius Medical Care could benefit from Donald Trump’s proposed US tariffs on imported generic drugs. Citi analyst Veronika Dubajova cited Hikma’s US-made volumes (over 75%) and Fresenius Kabi’s domestic production (over 70%). Tariffs are planned at 100% from Aug 2028 and 200% later. Both firms report soon.
How this was made
The 30-second read
Why it matters
Citi’s thesis is that manufacturers with a larger share of US-bound production already made domestically should be relatively better positioned, reducing exposure to the tariff levy.
Market read
This is a relative-winner sector read-through tied to a long-dated tariff policy, with near-term relevance mainly via positioning and upcoming earnings context.
What to watch
The article notes tariff scope and implementation details are sparse; final rules, exemptions, and how “generic medicines” are defined could materially change the read-across.
Background
The US president announced plans for a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.
Ticker impact
Citi argues Fresenius Medical Care’s Kabi division produces over 70% of its US volumes domestically, potentially reducing tariff pass-through risk.
Modest positive relative sentiment versus more import-dependent competitors, with limited immediate fundamental certainty.
The article cites domestic volume and input sourcing details, but lacks tariff scope clarity and provides no quantified earnings impact.
Market effects
Could shift relative valuation within generic and specialty pharma supply chains toward firms with higher US manufacturing content.
US-focused manufacturing capacity becomes a relative advantage versus offshore production hubs (notably India in the article’s framing).
Tariff policy uncertainty may increase cross-border supply-chain risk premia for generic drug manufacturers globally.
Counterpoint
Even with domestic manufacturing, companies may face demand shifts, pricing pressure, or downstream contract renegotiations that offset any tariff advantage.
Key entities
- companyHikma Pharmaceuticals PLC
London-listed drugmaker with over 75% of US sales volumes manufactured in the country, per Citi.
- companyFresenius Medical Care
Fresenius’s Kabi division produces more than 70% of its US volumes domestically, per Citi.
- analyst_firmCiti
Provides the relative-winner view based on domestic manufacturing mix and input sourcing.
- political_figureDonald Trump
Announced proposed generic-drug tariff schedule that drives the analysis.
